English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In this issue, we have reviewed the current status of imaging and blood-based biomarkers in translational lung cancer research. Clearly, some small but important initial steps have been made toward realizing precision medicine approaches for this disease, and research in this area has revealed significant opportunities to address unmet needs and validate imaging and blood-based biomarkers in clinical trials.

Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer